Michela Barioglio
Research Subjects
Michela Barioglio has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Adrian M. Isaacs
University College London
1 shared publication - Alessandro Marrero-Gagliardi1 shared publication
- Alexander J. Cammack
Washington University School of Medicine
1 shared publication - Christoph Schweingruber
Department of Biochemistry and Biophysics, Stockholm University, Svante Arrhenius v. 16C, 106 91 Stockholm, Sweden
1 shared publication - Christopher E. Shaw
UK Dementia Research Institute Centre at King’s College London, School of Neuroscience, King’s College London, London, UK
1 shared publication - Eugeni Ryadnov
UCL Queen Square Motor Neuron Disease Centre and Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK
1 shared publication
Latest Publications
- Open Access
U7 small nuclear RNA splice-switching therapeutics for STMN2 and UNC13A in Amyotrophic Lateral Sclerosis
TDP-43 nuclear depletion in amyotrophic lateral sclerosis (ALS) causes de-repression of cryptic exons (CEs) in multiple transcripts, including UNC13A and STMN2 , disrupting synaptic transmission and neurite outgrowth. We developed a therapeutic U7 snRNA (tU7) approach that suppresses TDP-43-dependent mis-splicing, restores target gene expression, rescues neuronal functions in human iPSC-derived neurons, and shows target engagement in vivo , positioning tU7-mediated splicing correction as a promising therapeutic strategy for ALS.
Open AccessU7 small nuclear RNA splice-switching therapeutics for STMN2 and UNC13A in Amyotrophic Lateral Sclerosis
TDP-43 nuclear depletion in amyotrophic lateral sclerosis (ALS) causes de-repression of cryptic exons (CEs) in multiple transcripts, including UNC13A and STMN2 , disrupting synaptic transmission and neurite outgrowth. We developed a therapeutic U7 snRNA (tU7) approach that suppresses TDP-43-dependent mis-splicing, restores target gene expression, rescues neuronal functions in human iPSC-derived neurons, and shows target engagement in vivo , positioning tU7-mediated splicing correction as a promising therapeutic strategy for ALS.